

Journal Article

Selective biomarkers for inflammation and infection are associated with post-operative complications following transperineal template prostate biopsy (TTPB): a single-centre observational clinical pilot-study

Snyper, N.Y.F., Pike, J., Ekwueme, K. *et al*

This article is published by BMC. The definitive version of this article is available at:
<https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-022-00807-8>

Published version reproduced here with acknowledgement of [BY license
<https://creativecommons.org/licenses/by/4.0/>]

Recommended citation:

Snyper, N.Y.F., Pike, J., Ekwueme, K. *et al*. Selective biomarkers for inflammation and infection are associated with post-operative complications following transperineal template prostate biopsy (TTPB): a single-centre observational clinical pilot-study. *Eur J Med Res* **27**, 187 (2022). <https://doi.org/10.1186/s40001-022-00807-8>.

RESEARCH

Open Access



Selective biomarkers for inflammation and infection are associated with post-operative complications following transperineal template prostate biopsy (TTPB): a single-centre observational clinical pilot-study

Nana Yaa Frempomaa Snyper^{1,2,3,6}, Joanne Pike³, Kingsley Ekwueme^{2,3,5}, Iqbal Shergill^{1,2,3,4} and Stephen Fôn Hughes^{1,2,3*}

Abstract

Background: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are the most common prostate disorders in the UK, which cause considerable ill health in older men. Transperineal template prostate biopsy (TTPB) has emerged as a reliable procedure for the histopathological diagnosis of PCa and BPH due to its higher cancer detection rates. Although antiseptic preparation and antibiotic prophylaxis are used to ensure safety in patients undergoing surgical intervention, post-operative complications, such as infection and bleeding are still unavoidable, resulting in re-admissions, with resource implications. Currently, there is no biomarker profile to predict outcomes or monitor patients during the post-operative course. The main aim of this single-centre observational clinical pilot-study was to investigate the role of inflammatory and infection biomarkers following TTPB and their association with post-operative complications.

Methods: Forty-five patients scheduled for elective TTPB were recruited after informed consent at the Wrexham Maelor and Glan Clwyd Hospitals, North Wales, UK ($n = 45$). Prior to surgery, venous blood samples were collected at baseline and subsequently at 30, 120, and 240 min post-operatively. Urine samples were collected before and 120 min after the procedure. Serum procalcitonin (PCT), serum ferritin, and urine B₂MG analysis were done using enzyme-linked fluorescent assay (ELFA) and the magnetic Luminex[®] multiplex performance assay was used to analyse IL-6, IL-8, IL-10 and TNF- α plasma concentrations. Data on clinical outcomes were collected from patients' medical records.

Results: Following TTPB, significant ($p \leq 0.05$) increases were observed in uB₂MG, IL-6, IL-8, IL-10 and TNF- α . Significant decreases were observed in ferritin ($p \leq 0.05$). No significant change was observed in PCT concentration ($p \geq 0.05$). One patient developed an infection and severe haematuria post-operatively following TTPB.

Conclusion: Although not confirmative, changes seen in biomarkers such as uB₂MG, IL-10 and TNF- α in our observational clinical pilot-study may warrant further investigation, involving larger cohorts, to fully understand the role of

*Correspondence: Stephen.hughes6@wales.nhs.uk

¹ North Wales & Northwest Urological Research Centre, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

these biomarkers and their potential association with post-operative complications such as infection and bleeding which can develop following TTPB for the diagnosis of PCa and BPH.

Keywords: Transperineal template prostate biopsy (TTPB), Benign prostatic hyperplasia (BPH), Prostate cancer (PCa), Cytokines, Urine beta-2 microglobulin, Post-operative complications

Introduction

Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are the most common disorders of the prostate, which cause considerable ill health and have significant adverse effects on quality of life, especially in older men. In the United Kingdom (UK), about 52,254 new cases of PCa are diagnosed yearly (2016–2018), accounting for 27% of all new cancer cases in males [1]. BPH risk increases with age occurring in about 40% of men over 50 years.

Transperineal template prostate biopsy (TTPB) has emerged to be a well-tolerated procedure in the histological diagnosis of PCa and BPH. TTPB has a higher cancer detection rate and is highly recommended for repeat biopsy in men with previous negative biopsy, rising and persistently high PSA levels, and those with suspicious findings on multi-parametric magnetic resonance imaging (mpMRI) [2]. In addition, TTPB has become helpful in monitoring patients on active surveillance, as it offers a more accurate staging and guidance for subsequent management decisions [3, 4].

Although TTPB is well tolerated and strategies such as antiseptic skin preparation and antibiotic prophylaxis are used to ensure the safety of patients undergoing surgical procedures, the development of post-operative complications remains a serious concern [5]. There is still the potential for patients to develop complications such as infection, bleeding, and urinary retention due to the more extensive sampling of the prostate with multiple cores taken.

According to the British Association of Urological Surgeons (BAUS), following TTPB, (urinary tract infection) UTI occurs 1 in 100 patients (1%), sepsis occurs in less than 1 in 100 patients (<1%), haematuria requiring emergency admission for treatment occurs in 1 in 100 patients (1%), clot retention 1 in 50 patients (2%) and acute retention of urine 1 in 20 patients (5%) [6].

Several studies have reported cases of UTI and sepsis following TTPB [7] [8]. In a recent evaluation of almost 500,000 prostate biopsies performed in the UK National Health Service from 2008 to 2019, TTPB was used in 98,588 cases. Observation after 28 days following TTPB indicated that 310 (0.31%) developed sepsis 757 (0.77%) developed an infection and 950 (0.96%) developed UTI [9]. Haematuria is a common manifestation of blood loss after TTPB [10, 11]. Urinary retention is by far the

most common complication observed after TTPB with reported occurrence rates of 16% ($n=35$) [10], 6.3% ($n=110$) [12], and 7.9% ($n=379$) [13]. Tamhankar et al. [9] identified acute urinary retention as the most common reason for non-elective hospital admission following TTPB over the past decade in the UK, resulting in 28.58% of admissions.

While some of these complications such as UTI and urosepsis risk are lower in TTPB (<1.0%), it remains a well-known complication post-procedure. This may result in longer hospital stays, or re-admissions to hospitals with associated patient morbidity, resource implications, and reduced quality of life [10, 14].

TTPB, like any other surgical procedure, is often associated with a normal inflammatory response as part of the body's normal healing process [15]. During TTPB, due to the insertion of needles into the prostate and consequent tissue removal from several sections of the prostate, the damage to the vascular endothelium following the procedure can be appreciated. Consequently, results in an inflammatory response and activation of the haemostatic system, which involves dynamic interactions with plasma, erythrocytes, platelets, leukocytes, endothelial cells, and cells of the tissue parenchyma leading to the expression and secretion of various biomarkers.

The inflammatory response involves the synthesis of acute-phase proteins such as C-reactive protein (CRP), procalcitonin (PCT) and ferritin, leukocyte attraction and transmigration through the endothelium, and accumulation at the site of injury [16, 17]. There is also the release of various pro- and anti-inflammatory cytokines, such as IL-6, IL-8, IL-10, and TNF- α , which also enhances the upregulation of adhesion molecules that facilitate leukocyte recruitment [18].

The actions of these biomarkers may collectively cause a substantial amount of damage to host tissue, prolong an inflammatory response following TTPB, and lead to post-operative complications. In case of complications, the tissue damage is more significant, resulting in increased serum levels of such biomarkers. These increases may be adequately sensitive to enable early diagnosis of the same complications.

C-reactive protein (CRP), coagulation tests, and patient's history are routinely used to predict patients at high risk of post-operative infection complications [19, 20]. However, CRP is nonspecific, as its elevation

is associated with various disorders, including surgery. Notably, there is also a sparse consensus on coagulation tests for predicting post-operative bleeding [21, 22].

Studies have reported that the concentrations of these PCT [23, 24], urine beta-2 microglobulin (uB₂MG) [25, 26], serum ferritin [27–29] and cytokines (IL-6, IL-8, IL-10, and TNF- α) [30–32] can be detected in serum in the early stages of bacterial infections and have been shown to be excellent predictors of early post-operative bleeding and infectious complications.

However, the single measurement of most biomarkers is inadequate and nonspecific, suggesting that a biomarker profile containing multiple markers could be more appropriate [33, 34].

Although the understanding of the inflammatory response following surgery has recently advanced, details of inflammation and infection biomarkers and their interactions in patients undergoing TTPB and post-operative responses such as infection and bleeding remain obscure. Also, further evaluation of these biomarkers during the post-operative period following TTPB will lead urologists to a well-supported consensus regarding improving post-operative care for better clinical outcomes.

Currently, no biomarker profiles are available to confidently forecast post-operative complications after surgical intervention of the prostate.

Clinically, developing biomarker profiles could help predict patients with or at increased risk of developing post-operative complications in real time. This could subsequently be used to identify patients who require intensified treatment or important changes to their care. Potentially, this could improve patient outcomes and health care provision, while also expanding existing knowledge in a field that is not well established.

The main aim of this single-centre observational clinical pilot-study was to investigate the role of inflammatory and infection biomarkers following transperineal template prostate biopsy (TTPB) and their association with post-operative complications.

Methods

Patient recruitment

Ethical approval for this study was received from the Welsh Research Ethics Service (REC) 4 committee (REC4: 12/WA/0117) and were carried out in accordance with the ethical rules of the Helsinki Declaration and Good Clinical Practice.

Forty-five (45) consecutive patients scheduled for elective TTPB at the Urology department of the Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital and Glan Clwyd Hospital, North Wales, UK, was recruited after providing written informed consent ($n=45$).

TTPB procedure

TTPB was performed by Consultant Urological Surgeons as a day-case procedure with patients under either local (using 20 ml 1% xylocaine with adrenaline and 20 ml 1% lidocaine) or general (using 20 ml of 0.5% bupivacaine with adrenaline) anaesthesia in the lithotomy position. The procedure was performed as per standard protocol using a TRUS probe, brachytherapy template grid, and under direct ultrasound guidance, an 18-gauge biopsy needle was directed through the template grid to obtain biopsies. Biopsy cores were then taken from the left anterior, left lateral, left posterior, right anterior, right lateral, and right posterior zones of the prostate. The collected prostate biopsy samples were submitted for histopathological analysis at the Glan Clwyd Hospital.

Blood samples

Venous blood samples were collected pre-operatively, then at 30 min, 120 min, and 240 min post-operatively. Urine samples were also collected pre-operatively and 120 min post-operatively. Aliquots of plasma, serum, and urine were prepared and stored at -80°C at the Maelor Academic Unit of Medical and Surgical Sciences (MAUMSS) laboratory until analysis.

Measurement of inflammatory and infection biomarkers

Serum PCT, serum ferritin, and urine B₂MG concentrations in samples of patients was measured using VIDAS[®] B.R.A.H.M.S PCT[™] (PCT), VIDAS[®] ferritin assay and VIDAS[®] B2MG assay (Biomerieux, France), an automated quantitative test for the determination of analytes using an enzyme-linked fluorescent assay (ELFA). Plasma concentrations of IL6, IL8, IL10, and TNF- α were also determined performed using a customised Human High Sensitivity Cytokine Premixed Kit A supplied by R&D Systems, a Bio-technique brand, Minnesota, USA, using the Magnetic Luminex[®] performance assay multiplex kit designed for analysis using the Bio-Rad[®] Bio-Plex[®] 100 (Bio-Rad Laboratories Inc, USA),

Details of complications (fever, pain, infection, bleeding, and urine flow rates) experienced by patients ($n=45$) within 30 days post-biopsy were collected from patients' medical records via patients' notes and the BCUHB clinical portal. Significant complications were defined as any adverse event requiring intervention or readmission.

Statistical analysis

Statistical analysis of data collected in this research was carried out using SPSS version 28 licensed. The Shapiro–Wilk test was used to check data distribution for normality, where $p \geq 0.05$ was considered a normal distribution. When the data were normally distributed, the repeated

measures analysis of variance (ANOVA) between samples test was used with a 5% level of significance. When ANOVA revealed significant variation ($p \leq 0.05$), post hoc testing was performed using the Bonferroni test for pairwise comparisons of means. The Friedman test was used to analyse data that did not conform to normality (Shapiro–Wilk test $p \leq 0.05$). Where the Friedman test yielded statistical significance ($p \leq 0.05$), the Wilcoxon signed-rank test was used for subsequent tests.

When $p \leq 0.05$, statistical significance was accepted. Parametric data were presented as mean and standard deviation as error bars, with non-parametric data reported as median and 10th percentiles.

Results

Information provided in Table 1 represents a summary of the patient’s characteristics (e.g. age, height, weight, etc.).

Information provided in Table 2 represents a summary of the surgical details.

Information provided in Table 3 represents the histopathological characteristics of the study participants.

Changes in PCT concentrations following TTPB

Figure 1 represents changes in serum PCT concentrations following TTPB.

Friedman analysis showed no significant changes in serum PCT concentrations following TTPB, $\chi^2(3, n = 45) = 2.591, p = 0.459$. Serum PCT concentrations remained unchanged from pre-operative levels (0.05 ± 0.05 ng/mL) to 30 min (0.05 ± 0.05 ng/mL), 120 min (0.05 ± 0.05 ng/mL) and 240 min (0.05 ± 0.05 ng/mL) post-TTPB.

Results presented as median, \pm 10th percentile as error bars, $n = 45$.

Table 1 Summary of patients’ characteristics ($n = 45$)

Age	
Median	66 years
Range	54–77 years
Height	
Median	178 cm
Range	163–186 cm
Weight	
Median	86.9 kg
Range	60–138 kg
BMI	
Normal weight (18.5–24.9 kg/m ²)	8 patients
Overweight (25.0–29.9 kg/m ²)	23 patients
Obese class I (30.0–34.9 kg/m ²)	7 patients
Obese class II (35.0–39.9 kg/m ²)	5 patients
Obese class III (≥ 40.0 kg/m ²)	2 patients

Table 2 Summary of surgical details ($n = 45$)

Reason for TTPB	
Repeat biopsy due to negative TRUSPB	18 patients
Active surveillance	5 patients
Elevated PSA with abnormal findings on mpMRI	22 patients
PSA level before biopsy	
Median	6.8 ng/ml
Range	0.8–58.0 ng/ml
Prostate volume at biopsy	
Median	41 ml
Range	6.0–98.0 ml
Number of biopsy cores	
Median	29 cores
Range	7.0–61.0
Duration of TTPB	
Median	21 min
Range	5–45 min
Type of anaesthesia	
General	38 patients
Local	7 patients
Post-operative complications observed	
Infection (UTI/sepsis) and severe haematuria	1 patient
Severe pain	3 patients
Urine retention	1 patient
Complications requiring re-admission to hospital	1 patient

Changes in uB₂MG concentrations following TTPB

Figure 2 represents changes in urine uB₂MG concentrations following TTPB.

uB₂MG concentrations increased from the pre-operative value (0.07 ± 0.01 mg/mL) to 0.21 ± 0.04 mg/mL at 120 min post-op. The change observed was found to be significant using the Friedman test, $\chi^2(1, n = 45) = 16.892, p < 0.001$.

Results presented as median, \pm 10th percentile, as error bars, statistical significance after post hoc analysis is represented when $*p \leq 0.05$ compared with the pre-operative value, $n = 45$.




Changes in serum ferritin concentrations following TTPB

Figure 3 represents changes in serum ferritin concentrations following TTPB.

A Friedman test revealed that there was a significant decrease in serum ferritin concentrations following TTPB, $\chi^2(3, n = 45) = 39.411, p < 0.001$. Pre-operative levels of serum ferritin, (117.1 ± 66.6 ng/mL), decreased at 30 min (109.3 ± 56.9 ng/mL), then a slight increase at 120 min (109.5 ± 65.3 ng/mL) and at 240 min post-op (113.5 ± 60.8 ng/mL) although recorded values were lower than pre-operative levels. Post hoc Wilcoxon

Table 3 Histopathological characteristics of study participants (n = 45)

		Number of cases	%
Diagnosis			
BPH		16	35.6
PCa		29	64.4
PCa Gleason Score and group grade			
Low grade	GS 3+3 = 6 (Group grade 1)	7	24.1
Intermediate grade	GS 3+4 = 7 (Group grade 2)	16	55.2
High grade	GS 4+3 = 7 (Group grade 3) GS 4+4 = 8 (Group grade 4) GS 4+5 = 9 (Group grade 5)	6	20.7



signed-rank test showed that there was a significant decrease in serum ferritin levels at 30 min ($p < 0.001$), 120 min ($p < 0.001$) and 240 min ($p = 0.008$) post-TTPB, compared to pre-operative levels.


Results presented as median, \pm 10th percentile, as error bars, statistical significance after post hoc analysis is represented when $*p \leq 0.05$ compared with the pre-operative value, $n = 45$.

Changes in plasma IL-6 concentrations following TTPB

Figure 4 represents changes in plasma IL-6 concentrations following TTPB.

There was a significant increase in plasma IL-6 concentrations following TTPB as determined by the Friedman test $X^2(3, n = 45) = 35.054, p < 0.001$. Pre-operative IL-6 values (2.8 ± 1.0 pg/mL) slightly decreased at 30 min (2.7 ± 1.0 pg/mL), then increased at 120 (4.3 ± 2.4 pg/mL), and 240 min post-op (4.1 ± 1.8 pg/mL). Post hoc Wilcoxon signed-rank test showed that there was a significant increase in plasma IL-6 concentrations at 120 min ($p < 0.001$) and 240 min ($p < 0.001$) post-TTPB, compared to pre-operative levels.

Results presented as median, \pm 10th percentile, as error bars, statistical significance after post hoc analysis is represented when $*p \leq 0.05$ compared with the pre-operative value, $n = 45$.



Changes in plasma IL-8 concentrations following TTPB

Figure 5 represents changes in plasma IL-8 concentrations following TTPB.

A Friedman test revealed a significant increase in plasma IL-8 concentrations following TTPB, $\chi^2(3, n=45)=10.324, p=0.016$. Baseline IL-8 increased from pre-operative (2.82 ± 2.12 pg/mL) to (3.05 ± 2.26 pg/mL) at 30 min, then a slight decreased at 120 (2.97 ± 1.75 pg/mL), and a further decreased at 240 min post-op (2.73 ± 1.80 pg/mL). Post hoc Wilcoxon signed-rank test showed that there was a significant increase in plasma IL-8 concentrations at 30 min post-TTPB ($p=0.030$), compared to levels pre-operatively.

Results presented as median, ± 10 th percentile, as error bars, statistical significance after post hoc analysis is represented when $*p \leq 0.05$ compared with the pre-operative value, $n=45$.

Changes in plasma IL-10 concentrations following TTPB

Figure 6 represents changes in plasma IL-10 concentrations following TTPB.

There was a significant increase in plasma IL-10 concentrations following TTPB as determined by the Friedman test, $\chi^2(3, n=45)=24.392, p<0.001$. Plasma IL-10 concentrations increased from the pre-operative value (1.30 ± 0.76 pg/mL) following TTPB to levels (3.06 ± 1.02 pg/mL) at 30 min, a further increase at 120 (3.43 ± 0.94 pg/mL), and then decreased at 240 min post-op (2.90 ± 0.92 pg/mL). Post hoc Wilcoxon signed-rank test showed that there was a significant increase in plasma IL-10 concentrations at 30 min ($p<0.001$) and 120 min ($p<0.001$) and a subsequent decrease at 240 min ($p<0.001$) post-TTPB, when compared to pre-operative measurements.

Results presented as median, ± 10 th percentile, as error bars, statistical significance after post hoc analysis




Fig. 6 Changes in plasma IL-10 concentrations following TTPB

is represented when $*p \leq 0.05$ compared with the pre-operative value, $n=45$.

Changes in plasma TNF- α concentrations following TTPB

Figure 7 represents changes in plasma TNF- α concentrations following TTPB.

There was a significant increase in plasma TNF- α concentrations following TTPB as determined by the Friedman test, $\chi^2(3, n=45)=23.295, p=0.022$. Plasma TNF- α concentrations increased from the pre-operative value (15.89 ± 8.50 pg/mL) following TTPB to levels (15.91 ± 8.99 pg/mL) at 30 min, a decrease at 120 min (14.98 ± 8.80 pg/mL), and then increased at 240 min post-op (16.41 ± 8.62 pg/mL). Post hoc Wilcoxon signed-rank test showed a significant decrease in plasma TNF- α concentrations at 120 min ($p<0.001$) and an increase at 30 min ($p=0.007$) and 240 min ($p=0.003$) post-TTPB when compared to pre-operative levels.

Results presented as median, ± 10 th percentile, as error bars, statistical significance after post hoc analysis is represented when $*p \leq 0.05$ compared with the pre-op value, $n=45$.




Fig. 5 Changes in plasma IL-8 concentrations following TTPB




Fig. 7 Changes in plasma TNF- α concentrations following TTPB

Changes in biomarkers of inflammation and infection and their association with post-operative complications

One participant (participant 11) with BPH, age 54 years, height 178.5 cm, weight 91 kg and BMI of 29 kg/m² developed post-operative complications 3 days after TTPB. He was admitted to the emergency department of the Wrexham Maelor Hospital with pain, severe haematuria, and fever (38.5 °C). Routine blood results on readmission showed an increase in leukocytes—16.0 × 10⁹/L (normal reference range: 4.0–11.0 × 10⁹/L), neutrophils—13.8 × 10⁹/L (normal reference range: 1.7 –7.5 × 10⁹/L) and C-reactive protein—57 mg/L (normal reference range: <5 mg/L). Urinalysis showed high leukocytes (3 +), protein (3 +), and blood (4 +) with visible blood clots. Further investigation revealed UTI leading to epididymo-orchitis, and he was hospitalised for 3 days and treated.

Figure 8 shows the changes in urine uB₂MG concentrations for participant 11 (pre-op—0.0 µg/ml and 120 min post-op—0.42 µg/ml) compared to the average study group who did not present any post-operative complications (pre-op—0.07 µg/ml and 120 min post-op—0.21 µg/ml).

Compared with the average group response, participant 11 had higher uB₂MG concentrations post-TTPB. This could suggest that uB₂MG could be a sensitive marker for predicting infection following TTPB.

Results presented as median, ±10th percentile as error bars, n = 45.

Figure 9 shows changes in plasma IL-10 concentrations for participant 11 (pre-op—1.29 pg/ml, 30 min post-op—21.1 pg/ml, 120 min post-op—14.05 pg/ml and 240 min post-op—13.09 pg/ml), compared to the average study group who did not experience any post-operative complications (pre-op—1.30 pg/ml, 30 min post-op—3.06 pg/ml, 120 min post-op—3.43 pg/ml and 240 min post-op—2.90 pg/ml).




Fig. 8 Changes in uB₂MG concentrations for Participant 11 compared to the average group




Fig. 9 Changes in plasma IL-10 concentrations for Participant 11 compared to the average group

Compared with the average group response, participant 11 had a high plasma IL-10 concentration at all time points post-TTPB. This further suggests IL-10 could be a sensitive biomarker for predicting infection and bleeding following TTPB.

Results presented as median, ± 10th percentile as error bars, n = 45.

Figure 10 shows changes in plasma TNF-α concentrations for participant 11 (pre-op—11.72 pg/ml, 30 min post-op—20.73 pg/ml, 120 min post-op—18.49 pg/ml and 240 min post-op—19.26 pg/ml), compared to the average study group who present no post-operative complications (pre-op—15.89 pg/ml, 30 min post-op—15.91 pg/ml, 120 min post-op—14.98 pg/ml and 240 min post-op—16.41 pg/ml).

Compared with the average group response, participant 11 had higher plasma TNF-α concentrations post-TTPB. This further highlights the potential of TNF-α as




Fig. 10 Changes in plasma TNF-α concentrations for Participant 11 compared to the average group

a sensitive biomarker for predicting UTI and haematuria following TTPB.

Results presented as median, \pm 10th percentile as error bars, $n = 45$.

Discussion

This single-centre observational clinical pilot-study intended to investigate the role of selective biomarkers for inflammation and infection (PCT, ferritin, uB₂MG, IL-6, IL-8, IL-10 and TNF- α) following TTPB and their association with post-operative complications such as infection and bleeding. This study found that following TTPB, there are significant changes in some inflammatory and infection biomarkers, namely uB₂MG, IL-6, IL-8, IL-10 and TNF- α .

PCT is a potent acute-phase reactant and increased PCT concentrations have been associated with sepsis and bacterial infection [23, 24]. Surprisingly, contrary to reported studies, the study found no significant changes in serum PCT concentrations following TTPB. Like the average group response, participant 11, who developed an infection following the procedure, showed no change in PCT concentrations. The observation of no significant change in PCT concentrations following TTPB could be due to the timings of sample collection (<4 h). Probably the time was too short to observe an increase in PCT in patients with complications. PCT has a half-life of 24 h, concentrations begin to rise within 3 to 4 h of bacterial infection and reach their peak after 12–24 h [35]. This finding may also suggest that the post-operative course of PCT may differ based on the type of surgical procedure.

Several studies have reported that patients with UTI express increased concentration of uB₂MG, and it has been suggested to be helpful in differential diagnosis and early detection of UTI [25, 26]. In agreement with previous reports [26, 27], our data follow a similar pattern of increased concentration following TTPB.

In agreement with Fang et al. and Jung et al. [25, 26], the patient (participant 11) who developed an infection following TTPB had higher uB₂MG concentrations compared with the average group response (Fig. 8). This further suggests that uB₂MG could be a sensitive marker for UTI following TTPB.

Increased serum ferritin concentrations have been associated with the severity of sepsis in children and the risk of early bacterial infection in adults [27–29]. In comparison to others [28–30], the present study demonstrated a significant decrease in serum ferritin levels at all times points measured post-TTPB, although these changes were minimal and were not of any clinical significance.

Increased IL-6, IL-8, IL-10 and TNF- α concentrations have been reported following surgical procedures and in

the early stages of bacterial infections both in adults and children [30–32].

The present study found a significant increase in plasma IL-6 concentrations at 120 min and 240 min post-TTPB, which follows a similar pattern of change as reported after transurethral resection of the prostate (TURP) [36] and shock wave lithotripsy for kidney stones [37], suggesting an immune and stress (inflammatory) response to the procedure.

Plasma IL-8 concentrations showed a significant increase post-TTPB, and this supports the report by Yuan [36], who also observed an increase in IL-8 an hour post-TURP. The significant increase in plasma IL-8 concentrations observed in this study is consistent with reports that an acute-phase immune response occurs within 2 h of stimuli challenge [38].

Interestingly, Plasma IL-10 concentrations significantly increased following TTPB. Our data differ from Hughes et al. [37], who reported no significant changes to IL-10 concentrations post-operatively following shock wave lithotripsy (SWL), non-invasive urological procedure performed to treat small kidney stones. Normally, IL-10 is considered to have potent anti-inflammatory properties, but increased levels have been reported to be associated with infection. IL-10 inhibits pro-inflammatory cytokine response and killing of *Burkholderia pseudomallei* [39], and this pattern of increased IL-10 concentration was evident in the patient (participant 11) who developed complications in the present study.

The present study showed significant increases in plasma TNF- α concentrations following TTPB, with similar observations being reported by Hughes et al. [37] following SWL for the treatment of kidney stones. In line with reports Patel et al. [30] and Guan et al. [31], this study found that participant 11 had higher plasma TNF- α concentrations post-TTPB compared to the average group who did not develop any complications.

Collectively, the significant changes in uB₂MG, plasma IL-10 and TNF- α concentrations following TTPB as reported by the patient (participant 11) who developed complications, suggest that these biomarkers could provide a sensitive and reliable tool for monitoring patients following TTPB. Thus, they could be considered as part of a biomarker profile to help identify those patients at increased risk of developing infection and bleeding complications post-operatively.

Apart from the relatively small number of patients ($n = 45$) included in this study, the current study has several limitations, in that; this study cannot exclude that there might have been some missed up or down-regulation of specific biomarkers during the later post-operative period. It would have been helpful to have a further sampling beyond 4 h, possibly 24–48 h after

surgery. Additional sampling may accentuate any sustained changes to the various biomarkers and their association with complications. However, this was not feasible as TTPB is a strict day-case procedure at our hospital.

This study could not establish a significant association between biomarker changes and complications due to the low incidence of complications. In addition, it was not possible to draw clear conclusions about the specific effect of TTPB on biomarkers because of the lack of a control group of patients. It will also be interesting for future studies to assess the influence of antibiotic prophylaxis on the analysed biomarkers.

While this study might only initially be providing observational data, it can be appreciated that this research provides a scientific basis for future investigations involving more extensive multi-centre studies into routine and novel biomarkers and their correlation with clinical outcome. This would then subsequently provide further evidence for developing specific biomarker profiles that can be used in addition to, or in combination with, current management protocols for the identification of patients at higher risk of post-operative complications.

Conclusions

Although not confirmative, changes seen to biomarkers such as uB₂MG, IL-10 and TNF- α in our observational clinical pilot-study may warrant further investigation, involving larger cohorts, to fully understand the role of these biomarkers and their potential association with post-operative complications such as infection and bleeding which can develop following TTPB for the diagnosis of PCa and BPH.

Abbreviations

BPH: Benign prostatic hyperplasia; BAUS: The British Association of Urological Surgeons; CRP: C-reactive protein; IL-1: Interleukin 1; IL-1 β : Interleukin 1 beta; IL-6: Interleukin 6; IL-8: Interleukin 8; IL-10: Interleukin 10; NICE: National Institute for Health and Care Excellence; PCa: Prostate cancer; PCT: Procalcitonin; TTPB: Transperineal template prostate biopsy; TRUSPB: Transrectal ultrasound-guided prostate biopsy; TURP: Transurethral resection of the prostate; TNF- α : Tumour necrosis factor-alpha; UTI: Urinary tract infection; uB₂MG: Urine Beta-2 microglobulin.

Acknowledgements

Special thanks to the patients who kindly volunteered to participate in the study

Author contributions

Conceived and designed the experiments: SFH, IS, KE, JP. Performed the experiments: NYFS. Analysed the data: NYFS, SFH, IS. Wrote the paper: NYFS and SFH. All authors read and approved the final manuscript.

Funding

The authors would like to acknowledge the Institute of Biomedical Science (IBMS) and Ghana Scholarships Secretariat for their financial support.

Availability of data and materials

All data generated or analysed during this study are included in the published article.

Declarations

Ethics approval and consent to participate

This study was approved by the Welsh Research Ethics Service (REC) 4 committee via the Integrated Research Application System (REC 4:12/WA0117).

Consent for publication

Not applicable.

Competing interests

The authors declare that no conflicting interests exist.

Author details

¹North Wales & Northwest Urological Research Centre, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK. ²Maelor Academic Unit of Medical and Surgical Sciences, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK. ³Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, Wales, UK. ⁴Department of Urology, BCUHB Wrexham Maelor Hospital, Wrexham, Wales, UK. ⁵Department of Urology, BCUHB Glan Clwyd Hospital, Rhyl, Wales, UK. ⁶Pathology Division, 37 Military Hospital, Accra, Ghana.

Received: 12 July 2022 Accepted: 3 September 2022

Published online: 26 September 2022

References

1. CRUK. Prostate cancer statistics—cancer research UK. 2021. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer>. Accessed 8 June 2022.
2. Nafie S, Wanis M, Khan M. The efficacy of transrectal ultrasound guided biopsy versus transperineal template biopsy of the prostate in diagnosing prostate cancer in men with previous negative transrectal ultrasound guided biopsy. *Urol J*. 2017;14(2):3008–12.
3. Sarkar D, Ekwueme K, Parr N. Active surveillance following modified transperineal template guided saturation biopsy demonstrates a low rate of progression and conversion to radical treatment, with age and psa associated with upgrading upstaging and treatment. *Adv Cancer Prev*. 2017;2(121):2472–3429.
4. Muthuveloe D, et al. The detection and upgrade rates of prostate adenocarcinoma following transperineal template-guided prostate biopsy—a tertiary referral centre experience. *Cent Eur J Urol*. 2016;69(1):42.
5. NICE. Surgical site infections: prevention and treatment guidelines. NICE guidelines NG 125. 2019. <https://www.nice.org.uk/guidance/ng125/resources/surgical-site-infections-prevention-and-treatment-pdf-66141660564421>. Accessed 8 June 2022.
6. BAUS. Transperineal prostate biopsies—leaflet. 2021. https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/Transperineal%20biopsies.pdf. Accessed 8 June 2022.
7. Jacewicz M, et al. Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia in urology oncology seminars and original investigations. Amsterdam: Elsevier; 2021.
8. Günzel K, et al. Infection rate and complications after 621 transperineal MRI-TRUS fusion biopsies in local anesthesia without standard antibiotic prophylaxis. *World J Urol*. 2021. <https://doi.org/10.1007/s00345-021-03699-1>.
9. Tamhankar AS, et al. The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of hospital episode statistics data 2008–2019. *BJU Int*. 2020. <https://doi.org/10.1111/bju.15062>.
10. Bhatt NR, et al. Patient experience after transperineal template prostate biopsy compared to prior transrectal ultrasound guided prostate biopsy. *Cent European J Urol*. 2018;71(1):43–7.
11. Sarkar D, Ekwueme K, Parr N. Patient-reported experience of modified transperineal template guided saturation biopsy under general anaesthesia and without prophylactic catheterisation. *Urol Int*. 2016;96(4):479–83.

12. Huang S, et al. Significant impact of transperineal template biopsy of the prostate at a single tertiary institution. *Urol Ann.* 2015;7(4):428.
13. Skouteris VM, et al. Transrectal ultrasound-guided versus transperineal mapping prostate biopsy: complication comparison. *Rev Urol.* 2018;20(1):19–25.
14. Palmisano F, et al. Incidence and predictors of readmission within 30 days of transurethral resection of the prostate: a single center European experience. *Sci Rep.* 2018;8(1):6575.
15. Smajic J, et al. Systemic inflammatory response syndrome in surgical patients. *Med Arch.* 2018;72(2):116–9.
16. Levi M, van der Poll T. Inflammation and coagulation. *Crit Care Med.* 2010;38:S26–34.
17. Abdulkhaleq LA, et al. The crucial roles of inflammatory mediators in inflammation: a review. *Vet World.* 2018;11(5):627–35.
18. Ren G, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. *J Immunol.* 2010;184(5):2321–8.
19. Dolan RD, et al. Attitudes of surgeons to the use of postoperative markers of the systemic inflammatory response following elective surgery. *Ann Med Surg (Lond).* 2017;21:14–9.
20. Nakamoto S, Hirose M. Prediction of early C-reactive protein levels after non-cardiac surgery under general anesthesia. *PLoS ONE.* 2019;14(12):e0226032.
21. Chen D, et al. Postoperative bleeding risk prediction for patients undergoing colorectal surgery. *Surgery.* 2018;164(6):1209–16.
22. Yilmaz F, et al. Is it rational to study coagulations test routinely before operations and invasive procedure: single center retrospective study. *Int J Hematol Oncol Stem Cell Res.* 2019;13(3):140–5.
23. Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. *PLoS ONE.* 2018;13(11):e0206527.
24. Cong S, et al. Diagnostic value of neutrophil CD64, procalcitonin, and interleukin-6 in sepsis: a meta-analysis. *BMC Infect Dis.* 2021;21(1):384.
25. Fang J, et al. Detection of PCT and urinary β 2-MG enhances the accuracy for localization diagnosing pediatric urinary tract infection. *J Clin Lab Anal.* 2017;31(5):e22088.
26. Jung N, et al. Diagnostic accuracy of urinary biomarkers in infants younger than 3 months with urinary tract infection. *Korean J Pediatr.* 2018;61(1):24–9.
27. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol.* 2017;29(9):401–9.
28. Banchini F, Cattaneo GM, Capelli P. Serum ferritin levels in inflammation: a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. *World J Emerg Surg.* 2021;16(1):9.
29. Nandy A, et al. Serum ferritin as a diagnostic biomarker for severity of childhood sepsis. *Indian Pediatr.* 2021;58:1143–6.
30. Patel P, et al. Markers of inflammation and infection in sepsis and disseminated intravascular coagulation. *Clin Appl Thromb Hemost.* 2019;25:1076029619843338.
31. Guan J, et al. IL-6 and IL-10 closely correlate with bacterial bloodstream infection. *Iran J Immunol.* 2020;17(3):185–203.
32. Plesko M, et al. The role of CRP, PCT, IL-6 and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients. *Neoplasma.* 2016;63(5):752–60.
33. Brown JR, et al. Utility of biomarkers to improve prediction of readmission or mortality after cardiac surgery. *Ann Thorac Surg.* 2018;106(5):1294–301.
34. Tsuchiya M, et al. Reduction of oxidative stress a key for enhanced postoperative recovery with fewer complications in esophageal surgery patients: randomized control trial to investigate therapeutic impact of anesthesia management and usefulness of simple blood test for prediction of high-risk patients. *Medicine (Baltimore).* 2018;97(47):e12845.
35. Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature. *Pharmacotherapy.* 2018;38(5):569–81.
36. Yuan B-X. The effect of transurethral enucleation resection of the prostate for benign prostatic hyperplasia on immune and stress response. *J Surg.* 2016;4:95.
37. Hughes SF, et al. Shock wave lithotripsy, for the treatment of kidney stones, results in changes to routine blood tests and novel biomarkers: a prospective clinical pilot-study. *Eur J Med Res.* 2020;25(1):18.
38. Schinkel S, et al. Effects of endotoxin on serum chemokines in man. *Eur J Med Res.* 2005;10(2):76–80.
39. Kessler B, et al. Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of *Burkholderia pseudomallei*. *Sci Rep.* 2017;7:42791.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

